Juvenile Benign Prostatic Hyperplasia: A Case Report / 대한비뇨기과학회지

No abstract available.

A 24 week Double-blind, Placebo-controlled Study using Terazosin in Treatment of Benign Prostatic Hyperplasia / 대한비뇨기과학회지

The double-blind, placebo-controlled study was performed to evaluate the efficacy and safety of once-a-day terazosin in 35 patients with benign prostatic hyperplasia. The dose of terazosin was titrated to 5 mg during 4 week period and then maintained throughout 24 week follow up. In terazosin group(n= 18), the maximum flow rates improved 32% from 10.4ml/sec at baseline to 13.7ml/sec, and the mean flow rate improved 38% from 5.5ml/sec to. 7.6ml/sec after 24 weeks of treatment(p 0.06). Adverse event occurred in one case of the terazosin group. In summary, terazosin administered once-a-day improved the obstructive and irritative symptoms of BPH and urine flow rates. Terazosin was well tolerated.

A case of bilateral renal angiomyolipoma associated with tuberous sclerosis / 대한비뇨기과학회지

Renal angiomyolipomas are uncommon benign neoplasms composed of mature adipose tissue, thick-walled blood vessels and smooth muscle in varying proportions, which are found in more than half of the patients with tuberous sclerosis. When associated with tuberous sclerosis, they are usually small, bilateral and multifocal. We present a case of bilateral renal angiomyolipoma with tuberous sclerosis in a 33-year-old female.